eCommons@AKU
Community Health Sciences

Department of Community Health Sciences

9-30-2020

Healthcare utilisation and expenditure patterns for cardiometabolic diseases in South Asian cities: The CARRS study
Priti Gupta
Kalpana Singh
Roopa Shivashankar
Kavita Singh
Ajay Vamadevan

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_chs_chs
Part of the Cardiology Commons, Community Health and Preventive Medicine Commons,
Endocrinology, Diabetes, and Metabolism Commons, and the Epidemiology Commons

Authors
Priti Gupta, Kalpana Singh, Roopa Shivashankar, Kavita Singh, Ajay Vamadevan, V Mohan, Muhammad
Masood Kadir, Nikhil Tandon, K M. Narayan, Dorairaj Prabhakaran, and Mohammed K. Ali

Original research

Healthcare utilisation and expenditure
patterns for cardio-metabolic diseases in
South Asian cities: the CARRS Study
Priti Gupta  ,1 Kalpana Singh,1 Roopa Shivashankar,1 Kavita Singh,2
Ajay Vamadevan,1 V Mohan,3 Muhammad Masood Kadir,4 Nikhil Tandon,5
K M Narayan,6 Dorairaj Prabhakaran,1,2 Mohammed K Ali7

To cite: Gupta P, Singh K,
Shivashankar R, et al.
Healthcare utilisation and
expenditure patterns for
cardio-metabolic diseases
in South Asian cities: the
CARRS Study. BMJ Open
2020;10:e036317. doi:10.1136/
bmjopen-2019-036317
►► Prepublication history for
this paper is available online.
To view these files, please visit
the journal online (http://dx.doi.
org/10.1136/bmjopen-2019-
036317).

Received 12 December 2019
Revised 20 July 2020
Accepted 07 August 2020

© Author(s) (or their
employer(s)) 2020. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Priti Gupta;
priti2317@gmail.com

ABSTRACT
Objective To estimate average annual expenditures
per person, total economic burden and distress health
financing associated with the treatment of five cardio-
metabolic diseases (CMDs—hypertension, diabetes, heart
disease (angina, myocardial infarction and heart failure),
stroke and chronic kidney disease) in three metropolitan
cities in South Asia.
Design Cross-sectional surveys.
Setting We analysed community-based baseline data
from the Centre for cArdio-metabolic Risk Reduction
in South Asia (CARRS) Study collected in 2010–2011
representing Chennai and New Delhi (India), and Karachi
(Pakistan).
Participants We used data from non-pregnant adults
(≥20 years) from the aforementioned cities that responded
to a cost-of-illness questionnaire. We estimated health
utilisation and expenditures among those reporting taking
treatment(s) for the aforementioned CMDs in the last
1 year. We converted all costs to International Dollars
(Int$ 2011) and inflated to 2018 values. The annual costs
per person were stratified by city, sociodemographic
characteristics, contributor of costs and financing
methods. The total economic burden of CMDs for each
city was projected using age-standardised prevalence and
per-person costs of diseases reported in CARRS, applying
these to population data from the most recent census. We
also calculated distress financing (DF) as having to borrow
or sell assets to pay for CMD treatment and identified
sociodemographic groups at most risk of DF using multiple
regression.
Results Of 16 287 CARRS participants, 2883 (17.7%)
reported receiving treatment for CMDs. The total annual
expenditures reported per patient for CMDs ranged
from Int$358 to Int$2425. Medications constituted 46%
of total direct expenditures and out-of-pocket (OOP)
expenditures accounted for nearly 80% of financing these
health expenditures. Total economic burdens of CMDs
were Int$0.42 billion, Int$3.4 billion and Int$1.4 billion
in Chennai, New Delhi and Karachi, respectively. Overall,
36.1% experienced DF, and women (OR=4.4), unemployed
(OR=10.7) and uninsured (OR=8.1) adults experienced
higher odds of DF.
Conclusion CMDs are associated with large economic
burdens in South Asia. Due to most payments coming from
OOP expenditures and limited insurance, the odds of DF
are high.

Strengths and limitations of this study
►► First large community-based study from South Asia

with primary data collected for cost-of-illness estimation for cardio-metabolic diseases.
►► Calculation of economic burdens for entire cities
using prevalence and economic survey data from
the same population which is an ideal approach to
calculate cost of illness and loss of productivity for
a city.
►► First estimates of distress health financing from a
community-based study.
►► The health service utilisation and expenditure data
were self-
reported and are subject to reporting
biases.
►► Utilisation and cost of treatments were collected for
the previous year, therefore it is subjected to recall
bias.

BACKGROUND
Non-communicable disease (NCD) burdens
are increasing worldwide, especially in low/
middle-
income countries (LMICs). Cardiovascular diseases (CVD) and diabetes mellitus
(DM) account for nearly 50% of NCD deaths.1
Due to economic growth and development
in the past two decades in South Asian countries, the burden of NCDs is increasing at
nearly twice the rate in comparison to the rest
of the world.2 For instance, between 1990 and
2010, disability-adjusted life years from ischaemic heart disease and DM were estimated
to have increased by 73% and 104% in South
Asia, respectively, compared with 30% and
70% in other parts of the world.3
Growing NCDs is a challenge for the health
systems in South Asia that still contend with
infectious diseases and hence face a ‘double
burden’ of disease.4 Health systems in this
region are not yet equipped and engineered
to conduct early diagnosis and management
of chronic diseases like high blood pressure,
glucose or cholesterol. This requires robust
primary care facilities with specific screening
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programmes and access to health education, laboratory
facilities, and a consistent and reliable availability of
essential medicines.4–6
Due to lack of adequate publicly funded health facilities and limited health insurance coverage, most health
expenditures are out-of-pocket (OOP) causing substantial economic impacts for individuals, households and
communities.7–11 In this context, a comprehensive evaluation of the economic burden of cardio-metabolic diseases
(CMDs) is valuable so that the financial burden of these
diseases is adequately addressed in the universal health
coverage reforms in these countries.12 Few published
reports had evaluated the economic burden of CMDs.7 10
However, existing studies have suffered from methodological inconsistencies, small sample sizes and limited
availability of highly precise disease prevalence estimates.
To address gaps in understanding of average per-person
annual spending on CMDs and their sources of financing,
we analysed costs of care for five CMDs namely: hypertension (HTN, DM, heart disease (HD), stroke (ST) and
chronic kidney diseases (CKD) from a large community-
based study in India and Pakistan.
METHODS
Data collection
We used data from the baseline survey of the Centre for
cArdiometabolic Risk Reduction in South Asia (CARRS).
The details of the CARRS Study are published elsewhere.13 14 In short, CARRS recruited 16 287 adults aged
≥20 years using multistage cluster random sampling
from urban cities of Chennai and New Delhi (India)
and Karachi (Pakistan) over 2010–2011. Trained interviewers collected data through household interviews in
local languages using standardised questionnaires and
obtained anthropometric and blood pressure measurements. Fasting blood and urine samples were collected
either at home (Karachi) or at local camps (New Delhi
and Chennai). The cost data questions were based on
the Initiative for Cardiovascular Health Research in the
developing countries macroeconomic study.15
We piloted the questionnaires before the survey and
interviewer debriefing methods were used to assess any
difficulty or variation in understanding of the items in
the questions; the wording of the questionnaires was then
modified accordingly. Participants were asked if they
received either outpatient (OP) or inpatient (IP) hospitalisation treatment for one or more CMDs—HTN, coronary heart disease (CHD: angina, myocardial infarction
or heart failure), ST, DM or its complications, and CKD in
the previous 12 months. If affirmative for OP treatment,
participants were asked the number of visits and medical
expenditures for each of the following categories: consultation fees, laboratory or radiological tests, medications,
physical therapy and home nurse care for each visit in the
past 12 months. If the participant was hospitalised for the
above-mentioned CMDs, then they were asked about the
number of times hospitalised, length of hospital stay(s),
2

and associated costs of hospital stays, costs of any surgical
or other procedures, lab tests and medications for each
hospitalisation in the past 12 months.
Additionally, for each OP visit and/or hospitalisation,
we collected data on direct non-medical expenditures
such as expenses on travel to and from clinic/hospital,
time spent waiting at the clinic, consultation time (for
OP), and the number of days spent by the respondent
and their caregivers in the hospital (for IP).
We also collected information on the type of healthcare
setting—government, private, charity or other. Further,
participants were asked about the source(s) of financing
used (own savings, payment by family members, insurance,
loans (relatives/ friends or banks/other lenders) and sale
of assets) and the proportion of healthcare expenditures
that were derived from each of these sources.
Variable definitions
Covariates
We used participants’ reported age, gender, marital status,
education, employment status and occupation as covariates. Based on participants’ responses, we categorised
education level (up to primary schooling, high school
or secondary, college graduation and above); wealth;
employment status (employed, homemaker, student,
unemployed, retired) and occupation (not working
outside the home, unskilled/semiskilled, trained/skilled,
white-collar). For calculating wealth, we used an index
of household amenities and assets. We used principal
components analysis methods14 and categorised wealth
in tertiles. Details of these methods are provided in a
previous publication.13
Per-patient expenditures
We used cost-of-illness methods to calculate the economic
burdens of CMDs. To provide comprehensive estimates of
health expenditures, we included both direct medical and
direct non-medical expenditures of each disease annually.16 We derived direct medical expenditures for each
CMD by adding the expenditures reported by participants
for medications, lab investigations, OP consultations and
hospitalisations. We calculated direct non-medical expenditures by aggregating participant-
reported transportation costs to and from the clinic/hospital and the costs
of boarding and lodging of attendants (only in the case
of hospitalisation). We estimated total direct expenditures by adding direct medical and non-medical expenditures.17 Here, we report annual per-patient expenditures
for individual CMDs—DM, HTN, CHD, ST and CKD—
and combinations of these: (1) DM+HTN and (2) HTN/
DM+HD/CKD/ST (ie, hypertension or diabetes with any
of heart disease, chronic kidney disease, and/or stroke).
Indirect costs (ie, productivity loss) were estimated on
the basis of the number of days lost for consultations,
hospitalisations or treatments17 reported by participants
of economically productive age (20–64 years).18 We used
the time spent in the clinic (waiting/consultation or
for investigations) and the number of days hospitalised
Gupta P, et al. BMJ Open 2020;10:e036317. doi:10.1136/bmjopen-2019-036317
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Figure 1

Annual mean cost per person of cardio-metabolic diseases in three cities in South Asia.

for this calculation. We considered less than 4 hours as
half a day loss and 4 hours or more as loss of an entire
day (considering an average of 8 working hours a day as
the standard). Since individual-level income data were
not available to estimate productivity losses, we used
minimum wage to compute indirect costs due to illness.
The number of days lost for each participant was then
multiplied by the minimum wage for that city in the
year 2017–2018. Minimum wages used for Chennai, New
Delhi and Karachi were 352 Indian rupees (Int$23.3),19
534 Indian rupees (Int$35.3)20 and 500 Pakistani rupees
(Int$20.5) per day,21 respectively.
The total costs of diseases were calculated by adding
direct and indirect costs (figure 1). We extrapolated these
data to estimate the total economic burden for each city.
We estimated the portion of expenditures that were OOP
by subtracting the amounts paid by insurance from total
direct expenditures.22
Distress financing
Participants were considered to be incurring distress
financing (DF) if the participants reported that their
source of financing treatment of CMDs included
borrowing money from relatives or friends, taking loans
from banks or other lenders, or selling assets.23
We converted all reported direct and indirect expenditures in Indian rupees and Pakistani rupees to 2011
Purchasing Power Parity-adjusted International Dollars
(Int$), the year for which data were collected and
presented in this paper.24 We inflated these costs to the
2018 US$ value.25 26
Data analysis
Sampling weights were used to account for the complex,
multistage design of the CARRS surveys to ensure that the
findings are representative of each city. Demographic and
socioeconomic profiles were described as percentages
(with 95% CIs), from each city and cumulatively.
For all medical expenditures, each unit of resource use
was multiplied with their frequency in the last 1 year, to
calculate the annual cost for that category. The expenditure on OP and IP treatments were presented as means
(SE). Given that cost data were unlikely to be normally
distributed, the bootstrap method was used to calculate
Gupta P, et al. BMJ Open 2020;10:e036317. doi:10.1136/bmjopen-2019-036317

SEs and 95% CIs were estimated for average costs.27 We
also estimated individual expenditures across different
age groups, socioeconomic groups, educational, occupation groups and cities.
We estimated what proportion of health expenditures
were financed through different means: OOP expenditures, insurance and others. We then calculated the
proportion of adults that needed to avail of DF to cover
health expenditures. Then, we used univariate and
multivariate logistic regression to assess which social,
demographic and clinical factors were associated with
higher probability of DF. The multivariate models were
constructed using those variables that were significant
(p<0.1) in the univariate models using a forward stepwise
approach.
To calculate the economic burden for each city, we calculated the size of the at-risk population (ie, age ≥20 years)
from the age-specific distributions of the populations of
New Delhi, Chennai and Karachi using the latest available
census data.28 29 For diagnosed CMDs, we estimated prevalence in each city using self-reported physician-diagnosed
DM, HTN, CHD, ST and CKD from the CARRS survey. For
DM and HTN, we also estimated the total prevalence (both
diagnosed and undiagnosed) by including participants
who did not report DM or HTN, but had measured blood
pressure ≥140/90 mm Hg (for HTN) and measured fasting
plasma glucose ≥126 mg/dL or glycated haemoglobin
HbA1c ≥6.5% (for DM). The size of the affected population
was calculated by multiplying the age-standardised prevalence of disease from the CARRS survey with the population at risk in each city. Prevalence was standardised to the
2010 world population, to compare these estimates with
other global cities that have different population structures.
Then, the per-patient average annual cost for each disease
was applied to the size of the affected population, to get
the total estimated cost of the disease for the city using the
following equation:
Cost projections for city=size of the affected population×nnual per-
person expenditures for the disease
where the size of affected population=age-standardised
prevalence for the disease (standardised to world population 2010)×size of the population aged 20 years and
above/100.
3

BMJ Open: first published as 10.1136/bmjopen-2019-036317 on 30 September 2020. Downloaded from http://bmjopen.bmj.com/ on November 3, 2020 at Pakistan:BMJ-PG Sponsored.
Protected by copyright.

Open access

STATA V.12.1 (STATA Corporation, College Station,
Texas, USA) was used for statistical analysis.
Patient and public involvement
It was not appropriate or possible to involve patients or
the public in the design, or conduct, or reporting, or
dissemination of our research.
Role of the funding source
The funding source had no role in the design of this study
and will not have any role during its execution, analyses,
interpretation of the data or decision to submit results.

RESULTS
Out of the 16 287 recruited participants, 3707 had self-
reported CMDs (HTN, CHD, ST, DM and/or CKD).
However, only 2883 (78%) had received treatment in
the prior year. Nearly 14% of patients with CHD, 63% of
patients with ST and 45% of patients with CKD reported
not receiving treatment in the last 12 months (see online
supplemental table S1).
Table 1 presents demographic, socioeconomic and
CVD risk factor characteristics of the 2883 respondents
who were treated for CMDs in the prior year. The mean
age of participants was 51.4 (SD=11.4) years, and women

Table 1 Demographic and socioeconomic characteristics of participants (who provided cost data) across all cities (total
N=2883)
Chennai (N=1228)

New Delhi (N=1021)

Karachi (N=634)

Total (N=2883)

% 95% CI

% 95% CI

% 95% CI

% 95% CI

Age (N=2883)
 <45 (n=677)

32.6 (26.1 to 39.7)

25 (18.9 to 32.3)

27.3 (17.2 to 40.3)

28.6 (24.0 to 33.6)

 45–59 (n=1319)

42.9 (36.5 to 49.6)

50.6 (41.9 to 59.4)

44.8 (31.7 to 58.7)

46.2 (40.6 to 52.0)

 >60 (n=887)

24.5(19.7 to 30.1)

24.3 (18.2 to 31.7)

27.9 (18.4 to 39.9)

25.2 (21.2 to 29.7)

 Mean age

50.5 (49.1 to 52.0)

52.3 (50.8 to 53.8)

51.6 (48.9 to 54.3)

51.4 (50.4 to 52.5)

 Male (n=1255)

41.3 (35.1 to 47.7)

49.3 (40.5 to 58.1)

36.6 (25.3 to 49.6)

43.2 (37.9 to 48.7)

 Female (n=1628)

58.7 (52.3 to 64.9)

50.7 (41.9 to 59.5)

63.4 (50.4 to 74.7)

56.8 (51.3 to 62.1)

Gender (2883)

Education (2883)
 Up to primary schooling (n=671)

21.6 (18.4 to 25.2)

14.5 (11.1 to 18.7)

34 (28.9 to 39.6)

21.7 (19.3 to 24.3)

 High school to secondary (n=1727)

71.1 (67.2 to 74.7)

51.5 (47.6 to 55.3)

52.8 (47.6 to 58.0)

59.6 (57.1 to 62.2)

7.3 (5.5 to 9.6)

34.1 (29.4 to 39.1)

13.1 (9.3 to 18.2)

18.6 (16.0 to 21.6)

37.9 (33.6 to 42.4)

45.6 (38.8 to 52.6)

26.6 (19.9 to 34.6)

38.2 (34.4 to 42.2)

 Graduation and above (n=485)
Employment status (2883)
 Employed (n=1045)
 Student (n=32)

1.6 (0.7 to 3.7)

0.5 (0.2 to 1.6)

46.3 (40.9 to 51.9)

42.1 (34.8 to 49.8)

50.7 (41.4 to 59.9)

 Retired (n=307)

7.3 (5.3 to 9.9)

9.8 (6.9 to 13.6)

10.7 (6.7 to 16.8)

9 (7.2 to 11.1)

 Unemployed (n=166)

7 (4.9 to 9.8)

2 (1.2 to 3.1)

9 (6.5 to 12.3)

5.5 (4.4 to 7.0)

 Housewife (n=1333)

3 (1.7 to 5.1)

1.5 (0.9 to 2.5)
45.7 (41.2 to 50.3)

Occupation (2883)
 Not working (n=1838)

62.1 (57.6 to 66.4)

54.4 (47.4 to 61.2)

73.4 (65.4 to 80.1)

61.8 (57.8 to 65.6)

 Semiskilled/unskilled (n=353)

19.2 (16.2 to 22.7)

8.6 (6.2 to 11.9)

9.5 (6.8 to 13.2)

13.1 (11.1 to 15.3)

 Trained/skilled (n=587)

17.7 (14.7 to 21.2)

28.8 (24.2 to 33.9)

14.2 (9.9 to 19.8)

21.1 (18.4 to 24.0)

8.2 (5.7 to 11.6)

2.9 (1.6 to 5.2)

4.1 (3.0 to 5.5)
21.2 (18.5 to 24.1)

 White collar (n=105)

1 (0.5 to 1.7)

Wealth index (2883)
 1 (n=637)

35.3 (31.1 to 39.7)

12.7 (9.6 to 16.8)

9.9 (8.1 to 12.1)

 2 (n=960)

38.6 (34.6 to 42.7)

19.2 (16.0 to 22.8)

41.7 (36.2 to 47.3)

32 (29.4 to 34.7)

 3 (n=1286)

26.1 (22.9 to 29.6)

68.1 (62.3 to 73.3)

48.4 (42.4 to 54.4)

46.8 (43.1 to 50.6)

Marital status (2883)
 Single (n=49)
 Married (n=2517)
 Widow/widower (n=303)
 Separated/divorced (n=14)

4

1.1 (0.6 to 1.9)

1 (0.5 to 1.7)

3 (1.7 to 5.2)

1.5 (1.1 to 2.0)

91 (88.5 to 93.0)

88.9 (86.3 to 91.1)

83.4 (79.2 to 86.9)

88.5 (86.7 to 90.1)

7.2 (5.3 to 9.7)
0.7 (0.4 to 1.4)

9.9 (7.9 to 12.4)
0.2 (0.1 to 1.0)

13.4 (10.0 to 17.8)
0.1 (0.0 to 0.9)

9.6 (8.1 to 11.3)
0.4 (0.2 to 0.7)
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constituted 56.8%. Most sociodemographic characteristics were distributed similarly among all the cities except
wealth and education. New Delhi had the larger proportions of participants in the highest wealth tertile (68%)
and graduate-
level education (34%), compared with
28.6% and 48.4% in Chennai, and 7.3% and 13.1% in
Karachi, respectively.
For both OP and IP care, more than 60% of participants reported using private health facilities. Across all
three cities, the primary source of financing was their
own household savings (52.5% in OP and 47.3% in IP).

Overall, insurance covered 3.3% of OP and 14.2% of IP
services used. Chennai had the lowest insurance coverage
(OP: 2.1%, IP: 8%) and highest government health facility
utilisation (OP: 28.1%, IP: 22.2%) among all three cities’
residents. The average time spent in OP visits and time to
each health facility was 60 and 28 min, respectively. The
average number of OP visits for all CMDs ranged from
5 to 11 per year, with the lower end of visits observed for
patients with DM and the higher end of visits observed for
patients with CKD (table 2).

Table 2 Type of health facility and source of financing for healthcare
Chennai

New Delhi

Karachi

Total
26.8 (24.4, 29.3)

Type of health facility (OP care) (2852)
 Government (n=786)

36.5 (32.7, 40.5) 26.1 (22.3, 30.4)

10.1 (7.9, 13.0)

 Private (n=2021)

62.4 (58.4, 66.3) 72.3 (68.1, 76.2)

87.5 (84.6, 90.0) 71.7 (69.2, 74.0)

 Charity (n=45)

1.1 (0.5, 2.1)

1.5 (0.8, 2.7)

2.3 (1.4, 3.7)

1.5 (1.1, 2.1)

Type of health facility (IP care) (n=114)
 Government (n=40)

48.7 (32.4, 65.4) 33.2 (17.7, 53.4)

27.1 (16.2, 41.8) 37.2 (28.6, 46.8)

 Private (n=71)

48.7 (32.5, 65.2) 66.8 (46.6, 82.3)

67.9 (53.2, 79.8) 60.1 (50.7, 68.9)

 Charity (n=3)

2.6 (0.3, 16.8)

0

5 (1.2, 17.9)

2.6 (0.8, 8.0)

 Time spent in OP per visit (min) (N=2875) (mean
(SD))

68.6 (56.4)

53.5 (63.7)

51.2 (55.8)

59.1 (59.5)

 Time spent to reach hospital/clinic per visit (min)
(N=2875) (mean (SD))

29.6 (21.1)

28.9 (26.2)

23.8 (18.8)

28 (23)

 Number of OP visit (N=2875) (mean (SD))

5.2 (5)

7.1 (9.7)

6.4 (8.1)

6.2 (7.9)

  
HTN

5.2 (4.9)

7.2 (10.2)

6.7 (9.4)

6.4 (8.6)

  
DM

4.5 (4.3)

5.6 (6.1)

6.5 (8.8)

5.2 (5.9)

  
HD

6.5 (6.5)

6.3 (8.5)

3.8 (4.6)

5.6 (7)

  
CKD

2.6 (1.3)

54.4* (43.6)

  
ST

7.2 (6)

6.9 (6.4)

  
HTN+DM

5.6 (5)

7.8 (8)

6.4 (5.7)

6.5 (6.5)

  
HTN/DM+HD/CKD/ST

6.5 (5.7)

9.7 (15.3)

6.6 (5.8)

7.6 (10)

4.8 (6.5)
10.7 (1)

11 (23.7)
8.1 (5.5)

OP visit financing source† (N=2876)
 Own saving (N=1511)

44.8 (41.0, 48.6) 61.3 (55.5, 66.8)

51.8 (46.8, 56.7) 52.5 (49.4, 55.6)

 Family members paid (N=1010)

28.1 (24.3, 32.2) 37 (31.5, 42.8)

45.5 (39.7, 51.4) 35.3 (32.4, 38.3)

 Insurance (N=94)

2.1 (1.2, 3.8)

 Other (government/charity hospital/borrowed from 28.1 (24.7, 31.8)
friend or bank) (N=366)

4.5 (3.3, 6.3)

3.2 (2.0, 5.0)

3.3 (2.6, 4.2)

2.4 (1.5, 4.1)

0.8 (0.3, 1.8)

12.4 (10.7, 14.4)

IP care financing source† (N=95)
 Own saving (N=44)

50.4 (30.9, 69.8) 51.6 (28.8, 73.8)

39.6 (21.5, 61.1) 47.3 (35.0, 59.9)

 Family members paid (N=35)

32.7 (16.8, 53.9) 19.4 (7.4, 41.8)

45.9 (30.9, 61.7) 33.5 (23.8, 44.9)

 Borrowed from friend, relatives or bank (N=4)

1.9 (0.4, 9.1)

9.3 (1.3, 44.0)

4 (0.5, 24.5)

4.5 (1.3, 14.2)

 Insurance (N=13)

8 (2.4, 23.6)

19.8 (7.6, 42.3)

18.2 (8.2, 35.5)

14.2 (7.7, 24.8)

 Other (government/charity hospital) (N=8)
 Distress health financing (N=2866)

22.2 (9.3, 44.3)
0
29.3 (25.5, 33.4) 37.2 (31.7, 43)

3.2 (0.4, 20.2) 10.5 (4.7, 21.7)
46.4 (40.9, 52.1) 36.1 (33.3, 39)

*Higher than other cities as one participant had 96 visits in last 1 year.
†Multiple responses.
CKD, chronic kidney disease; DM, diabetes mellitus; HD, heart disease; HTN, hypertension; IP, inpatient; OP, outpatient; ST, stroke.
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Per-patient expenditure
Total annual mean health expenditures for all CMDs in
Chennai, New Delhi, Karachi, and the average for all cities
were Int$467, Int$979, Int$684 and Int$708, respectively.
The total average annual direct and indirect expenditure
per person were Int$536 and Int$171, respectively (figure 1).
Overall, mean annual costs per patient for HTN, DM, CHD,
ST, CKD, HT+DM, and HT/DM+CHD/ST/CKD were
Int$358, Int$469, Int$1831, Int$2425, Int$870, Int$713 and
Int$2342, respectively. In all cities, average total OP expenditures were higher than IP expenditures. Medications constituted the majority (46%) of direct expenditures (see online
supplemental table S2).
Total direct and OOP expenditures were highest in the
age group 45–60 years. People with higher education had
more total direct and OOP expenditures. However, as a

percentage of OOP expenses, people in white-collar jobs
and of higher wealth index had the lowest expenditures
relative to their wealth/income (table 3).
Distress financing
DF for Chennai, New Delhi and Karachi were reported
by 29.2%, 37.2% and 46.4%, respectively, of participants
with CMDs (table 2). After adjustment for sociodemographic variables, city and insurance, and female gender,
unemployed individuals and people without insurance
were more likely to incur DF. Wealth and education were
not associated with DF (table 4).
Total economic burden (projections at population level)
reported CMDs were
Total economic burdens of self-
Int$0.4 billion, Int$3.4 billion and Int$1.4 billion in

Table 3 Sociodemographic correlates of direct and out-of-pocket (OOP) health expenditure
Variable

Total direct expenditure
cost (in Int$), mean (SE)

OOP expenditure (in Int$),
mean (SE)

OOP/total direct
expenditure (%)

Age (years)
 <45 (n=677)

370 (31.6)

312 (21.9)

84.4

 45–59 (n=1319)

606 (70.9)

447 (53.8)

73.8

 >60 (n=887)

596 (82.6)

453 (42.2)

76.1

 Male (n=1252)

610 (75.8)

467 (50.0)

76.6

 Female (n=1628)

480 (45.7)

367 (27.1)

76.5

 Up to primary schooling (n=671)

479 (99.8)

299 (21.0)

62.4

 High school to secondary (n=1727)

501 (40.0)

409 (32.9)

81.7

 Graduation and above (n=485)

716 (117.9)

545 (71.1)

76.1

 Employed (n=1045)

516 (62.)

372 (36.8)

72.1

 Student (n=32)

751 (297.4)

419 (139.1)

55.8

 Housewife (n=1333)

462 (38.7)

400 (32.3)

86.8

 Retired (n=307)

937 (199.8)

589 (88.1)

62.9

 Unemployed (n=166)

580 (178.3)

460 (164.2)

79.4

 Not working (n=1838)

548 (46.5)

434 (30.7)

548 (46.5)

 Semiskilled/unskilled (n=353)

306 (36.3)

268 (37.2)

306 (36.3)

 Trained/skilled (n=587)

587 (85.1)

421 (52.3)

587 (85.1)

 White collar (n=105)

824 (412.7)

456 (85.)

824 (412.7)

 1 (n=637)

278 (46.4)

227 (32.7)

81.7

 2 (n=960)

402 (34.7)

312 (22.9)

77.7

 3 (n=1286)

744 (71.2)

560 (51.9)

75.2

 Chennai (n=1228)

335 (30.4)

292 (24.4)

87.2

 New Delhi (n=1021)
 Karachi (n=634)

744 (71.4)
550 (84.9)

564 (57.6)
366 (38.8)

75.9
66.5

Gender

Education

Employment status

Occupation

Wealth index

City
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Table 4 Univariate and multivariate logistic regression for distress financing
Univariate analysis
OR (95% CI)

Multivariate analysis
P value*

OR (95% CI)

P value

Age (years) (2883)
 <45 (n=677)

Ref

 45–59 (n=1319)

1.1 (0.8–1.5)

0.5

1.1 (0.8–1.4)

Ref
0.33

 >60 (n=887)

1.5 (1.1–2.1)

0.006

1.3 (0.9–1.9)

0.21

Gender (2866)
 Male (n=1245)

Ref

Ref

 Female (n=1621)

8.2 (6.4–10.5)

<0.001

4.4 (2.8–7.1)

<0.001

 Up to primary schooling (n=671)

3.1 (2.2–4.4)

<0.001

1.3 (0.8–1.9)

0.14

 High school to secondary (n=1715)

1.7 (1.3–2.4)

0.001

1.2 (0.9–1.7)

0.21

 Graduation and above (n=484)

Ref

Ref

 Employed (1038)

Ref

Ref

 Student (32)

10.3 (4.6–23.2)

<0.001

8.9 (2.6–30.1)

<0.001

 Housewife (1327)

11.9 (8.8–16.2)

<0.001

6.6 (2.6–17.0)

<0.001

 Retired (302)

3.1 (2.2–4.6)

<0.001

5.5 (2.1–14)

<0.001

 Unemployed (167)

8.2 (5.1–13.2)

<0.001

10.7 (3.7–30.8)

<0.001

 Not working (n=1828)

15.3 (6.6–35)

<0.001

Omitted because of collinearity

 Semiskilled/unskilled (n=351)

2.1 (0.9–5.2)

0.1

2.1 (0.8–6)

0.10

 Trained/skilled (n=582)

1.4 (0.6–3.4)

0.4

1.5 (0.6–3.6)

0.50

 White collar (n=105)

Ref

 Education (2870)

Employment status (2866)

Occupation among employed (2866)

Ref

Wealth index (2866)
 1 (n=631)

Ref

 2 (n=955)

1.2 (0.9–1.7)

0.14

Not included in the model

 3 (n=1280)

1.1 (0.8–1.6)

0.4

Marital status (2866)
 Single (n=49)

Ref

 Married (n=2503)

1.9 (0.9–3.9)

Ref

 Widow/widower (n=300)

4.2 (1.9–9)

 Separated/divorced (n=14)

5.9 (1.5–23.5)

0.08

1.2 (0.8–1.7)

0.38

<0.001

1.8 (0.9–3.8)

0.12

0.012

1.6 (0.7–3.4)

0.28

City (2866)
 Chennai (n=1217)

Ref

 New Delhi (n=1018)

1.4 (1.04–2)

<0.001

2.4 (1.0–20.7)

Ref
<0.001

 Karachi (n=631)

2.1 (1.6–2.8)

<0.001

2.2 (1.7–2.7)

<0.001

<0.001

8.1 (3.8–17.1)

Insurance (2865)
 Yes (100)

Ref

 No (2765)

7.2 (3.5–14.9)

Ref
<0.001

2

*Χ test.

Chennai, New Delhi and Karachi, respectively. When we
assumed everyone with a CMD would need treatment
(both undetected and self-reported), the estimated total
city-
level costs would be Int$0.5 billion, Int$4.1 billion
and Int$2 billion, respectively for Chennai, New Delhi
and Karachi (see online supplemental tables S3 and S4).
Gupta P, et al. BMJ Open 2020;10:e036317. doi:10.1136/bmjopen-2019-036317

DISCUSSION
We calculated total costs of illness (direct and indirect)
and economic burdens of HTN, CHD, ST, DM and its
complications, and CKD based on participant reports
from a large survey of three major cities of South Asia.
Total annual mean economic costs for all CMDs in these
7

BMJ Open: first published as 10.1136/bmjopen-2019-036317 on 30 September 2020. Downloaded from http://bmjopen.bmj.com/ on November 3, 2020 at Pakistan:BMJ-PG Sponsored.
Protected by copyright.

Open access

three metropolitan cities of South Asia was Int$708. The
total annual costs per patient for individual CMDs and
combination of comorbid CMDs varied considerably
from Int$358 (for HTN) to Int$2342 (for patients with
multiple comorbidities, that is, HTN/DM with at least
one complication). Comparing this with gross domestic
product (GDP) per capita30 for India (Int$4635.9) and
Pakistan (Int$4309.8), our data show that the presence of
multiple comorbid CMDs can account for up to 40% of
per capita expenditures.31
We found New Delhi had the highest total cost of treatment among the three cities. This may be because New
Delhi has a larger population,28 29 a larger percentage of
participants in highest wealth index (New Delhi: 68%,
Chennai: 26%, Karachi: 48%), and a large percentage
of patients being treated in private for-
profit settings
compared with Chennai and Karachi. Of note, our
approach used participants’ reported expenditures
and these would be low or even nearly free for publicly
funded facilities. As a result, average and total costs in
Chennai were lower likely due to a higher percentage
of patients using government health facilities compared
with the other two cities. It is also possible that the costs
in for-profit facilities vary and are highest in New Delhi
compared with the other cities.30
Though total expenditure was highest among the
wealthiest group, the largest burden of OOP expenditures was observed in the least wealthy group. Previously published reports from India have also reported
high OOP expenditures in low socioeconomic
groups.32–34 This can lead to catastrophic payments
and impoverishment of households.32 35 Given limited
government financing (<2% of GDP) in both countries, private health facilities cater for the majority
of health service use, both OP (71.7%) and IP care
(60.1%), and household savings tend to be the most
common financing source (52.5% of OP and 47.3% of
IP). This heavy reliance on OOP expenditures (nearly
80%) is not surprising and mirrors findings from other
studies from India and other World Bank defined
LMICs. 8 35–37 For example, previous work from India, 38
Pakistan 39 and other 23LMICs shows that health insurance coverage dismally low for both OP (3.3%) and
IP care (14.2%). To address low insurance coverage
and high OOP expenditure, in the 2018–2019 union
budget, the government of India has announced the
Ayushman Bharat Programme to try to increase the
accessibility, availability and affordability of all level
of health services in India. 40 Evaluation of the impact
of these financing and policy decisions will be helpful
in guiding the future modification or continuation of
these programmes.
We found that medication accounts for the highest
proportion of direct expenditures, followed by investigations and consultation fees. This is similar to previous findings from India that analysed the National Sample Survey
Office data.8 This is also true for most other low-income
countries as found in a previous review from 2013.12 Since
8

medications accounted for the highest proportions of
OOP expenditures, discount pharmacies and prescription of generic medicines may be options to reduce financial burdens on patients. The government of India has
already initiated ‘Pradhan Mantri Bhartiya Janaushadhi
Pariyojana’41 and launched discounted pharmacies, that
is, Jan Ausahadhi Store (JAS)42 to increase the availability
of generic medicines. A cost analysis of JAS has shown
that most of the costs of medicines at JAS are lower than
branded ones.43
Overall, the prevalence of DF was 36.1% in our study.
A community-based study conducted in India also reports
40% DF in urban areas for IP care.44 Women, those that
are unemployed, and those without insurance were more
likely to experience DF. Wealth was not associated with
DF. In another study conducted in four LMICs including
India, DF was 65% for India which is markedly higher
than our study as that study was focused on recently hospitalised patients, though in that study, DF was also more
common among female and unemployed participants,
and participants without insurance.23 Insurance appears
to be a strong predictor of avoiding DF; as such, universal
health coverage may be an important avenue to potentially decrease the financial risks associated with CMDs. In
addition, the availability of government health facilities
may also lower total OOP expenditures, as was observed
in comparing costs in Chennai and the other cities.
CMDs require regular follow-up visits to health facilities
leading to loss of working time both for the patient and
caregivers; these non-medical and indirect costs contributed to 14% of the total economic cost in our study. Other
studies from India and Pakistan suggest indirect costs
for patients with DM and their caregivers were 28.76%
and 15%, respectively.39 45 Due to differences in methods
(minimum wage vs actual individual income), our estimates for indirect costs were likely conservative. In addition to health expenditures, the economies and societies
in India and Pakistan also suffer from lost productivity due
to deaths from HD, ST and DM amounting to $53 billion
and $3.5 billion, respectively over the period 2005–2015.46
These should also be factored into policy decisions
regarding action to address CMDs going forward.
Twenty-
two per cent of total participants with self-
reported CMDs did not report receiving any treatment.
Though they were not enumerated in this study, in the
absence of treatment, these individuals may experience
acute complications, which are hugely expensive resulting
in higher financial burdens and sufferings. Therefore,
awareness regarding regular treatment in CMDs and
more effective preventive and screening strategies are
required to prevent long-term disability.8
The high prevalence and economic cost of CMDs in
India and Pakistan underline the importance of policy
and governance to help steer current health system regulations toward more efficient use of healthcare and better
health outcomes. To address acute and chronic disease
needs, there is a need to develop a system that provides
high-quality, accessible and affordable services.47
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Strengths and limitations
To the best of our knowledge, this was the first large
community-
based study from South Asia with primary
data collected for cost-
of-
illness estimation for CMDs.
These data were representative of their respective cities.
We used age-standardised prevalence, standardised to the
world’s population in 2010 for calculation of economic
burdens to cities. Epidemiological (prevalence of CMDs)
and economic survey (direct medical and non-medical
cost, indirect cost and source of financing) data were
collected from the same population which is an ideal
approach to calculate cost of illness and loss of productivity for a city.9
Nevertheless, our study had some limitations. The
health service utilisation and expenditure data were
self-reported and are likely subject to reporting biases.
However, for community-level cost data collection, self-
report is the most common method used. Utilisation
and cost of treatment were collected for the last 1 year,
therefore it is subjected to recall bias. That said, it is
unclear which direction the recall bias would influence
our estimates—that is, were they higher or lower than in
reality? We expect that standardised training and protocols and stringent monitoring of surveys would have minimised these biases. For indirect cost calculations, due to
unavailability of data on attendant costs for OP visits, the
actual income of the participant, an actual number of
days lost for OP care and value of premature mortality
caused by CMDs, we expect tour indirect cost estimates
are extremely conservative. However, as indirect cost
contributes less than 15% of total economic costs, we
would not expect huge variation in total economic costs.
For the cost estimates for the undiagnosed, we cannot be
sure of this and would propose that the costs of people
with undiagnosed DM lie somewhere between 0.5 and 1.5
times what they are for the diagnosed. Therefore, we took
the midpoint of 1.0 times (or a 1:1 conversion). Due to
the unavailability of recent census data from Pakistan, we
used data from 1998 to calculate the population at risk,
which can lead to underestimation of total economic
burdens for Karachi. All calculated costs do not consider
subsidised health services and data to incorporate this
component are not available.

CONCLUSIONS
CMDs constitute a huge economic burden in South Asia.
Our analysis took the users’ perspective on expenditures
of-
illness approach. This study highand used a cost-
lights the direct, indirect and OOP expenditure CMDs
in three major cities of India and Pakistan. Importantly,
80% of direct expenditures were OOP and 36% reported
requiring DF. These findings highlight major gaps in
insurance coverage, health financing, and limited availability and utilisation of public health facilities.
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